Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd has announced record revenue and profit, declaring its first annual dividend, highlighting its strong financial performance. The company continues to make strides in the healthcare sector, particularly in Alzheimer’s research, by supporting decentralized trials and receiving funds from the Alzheimer’s Drug Discovery Foundation, which underscores its significant role in advancing therapeutic developments.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd, founded in Melbourne, Australia in 1999, operates in the healthcare and pharmaceutical industry. The company specializes in cognitive assessment technologies and services, with a focus on supporting clinical trials and healthcare professionals. Cogstate is listed on the ASX and has expanded its operations globally, including opening a US office and launching products like Cognigram™ for healthcare professionals.
Average Trading Volume: 82,586
Technical Sentiment Signal: Buy
Current Market Cap: A$284M
Find detailed analytics on CGS stock on TipRanks’ Stock Analysis page.